DK1064376T3 - GFR-alpha3 og dets anvendelser - Google Patents

GFR-alpha3 og dets anvendelser

Info

Publication number
DK1064376T3
DK1064376T3 DK99913993T DK99913993T DK1064376T3 DK 1064376 T3 DK1064376 T3 DK 1064376T3 DK 99913993 T DK99913993 T DK 99913993T DK 99913993 T DK99913993 T DK 99913993T DK 1064376 T3 DK1064376 T3 DK 1064376T3
Authority
DK
Denmark
Prior art keywords
receptor
homo
gfr
subunit
activation
Prior art date
Application number
DK99913993T
Other languages
English (en)
Inventor
Frederic J Desauvage
Robert D Klein
Heidi S Phillips
Arnon Rosenthal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1064376T3 publication Critical patent/DK1064376T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
DK99913993T 1998-03-23 1999-03-19 GFR-alpha3 og dets anvendelser DK1064376T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7912498P 1998-03-23 1998-03-23
US8156998P 1998-04-13 1998-04-13

Publications (1)

Publication Number Publication Date
DK1064376T3 true DK1064376T3 (da) 2006-07-24

Family

ID=26761638

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99913993T DK1064376T3 (da) 1998-03-23 1999-03-19 GFR-alpha3 og dets anvendelser

Country Status (12)

Country Link
US (4) US20050221330A1 (da)
EP (1) EP1064376B1 (da)
JP (2) JP4469935B2 (da)
AT (1) ATE320489T1 (da)
AU (1) AU765070B2 (da)
CA (1) CA2323072C (da)
DE (1) DE69930374T2 (da)
DK (1) DK1064376T3 (da)
ES (1) ES2262317T3 (da)
IL (2) IL138593A0 (da)
NZ (1) NZ506748A (da)
WO (1) WO1999049039A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
CN101043899B (zh) 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 重折叠转化型生长因子beta家族蛋白
WO2007042040A2 (en) * 2005-10-11 2007-04-19 Ns Gene A/S TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
EP2252196A4 (en) 2008-02-21 2013-05-15 Dexcom Inc SYSTEMS AND METHOD FOR PROCESSING, TRANSMITTING AND DISPLAYING SENSOR DATA
WO2011057347A1 (en) 2009-11-12 2011-05-19 Tgr Biosciences Pty Ltd Analyte detection
WO2011123795A1 (en) 2010-04-02 2011-10-06 Battelle Memorial Institute Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies
EP2786148A4 (en) * 2011-03-31 2015-12-16 Tgr Biosciences Pty Ltd DETECTION OF ANALYTES WITH A SINGLE IMMUNE TEST
CA2838818A1 (en) * 2011-06-09 2012-12-13 University Of Miami Methods of treatment for retinal diseases
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
CA2175893C (en) * 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
EP0888385B1 (en) * 1996-03-14 2003-08-20 Genentech, Inc. Gdnf receptor and uses thereof
US7138251B1 (en) * 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
IL126918A (en) * 1996-05-08 2007-06-03 Biogen Idec Inc Ret ligand (retl) for stimulating neural and renal growth
US6677135B1 (en) * 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
EP0846764A3 (en) * 1996-11-27 1998-09-30 Smithkline Beecham Plc Glial cell line-derived neurotrophic factor alpha receptor family
AU730430B2 (en) * 1997-02-18 2001-03-08 Genentech Inc. Neurturin receptor
WO1998053069A2 (en) * 1997-05-20 1998-11-26 Human Genome Sciences, Inc. Gdnf receptors
JP2002505576A (ja) * 1997-05-30 2002-02-19 アムジエン・インコーポレーテツド 神経栄養因子レセプター

Also Published As

Publication number Publication date
US20050221330A1 (en) 2005-10-06
US20100249034A1 (en) 2010-09-30
DE69930374D1 (de) 2006-05-11
DE69930374T2 (de) 2006-12-07
WO1999049039A2 (en) 1999-09-30
US20060216289A1 (en) 2006-09-28
WO1999049039A3 (en) 2000-02-10
US7691973B2 (en) 2010-04-06
AU3194499A (en) 1999-10-18
IL138593A (en) 2010-11-30
JP2009171974A (ja) 2009-08-06
ES2262317T3 (es) 2006-11-16
EP1064376A2 (en) 2001-01-03
JP2002507421A (ja) 2002-03-12
AU765070B2 (en) 2003-09-11
IL138593A0 (en) 2001-10-31
CA2323072C (en) 2011-05-24
US20070232535A1 (en) 2007-10-04
ATE320489T1 (de) 2006-04-15
EP1064376B1 (en) 2006-03-15
NZ506748A (en) 2002-10-25
CA2323072A1 (en) 1999-09-30
JP4469935B2 (ja) 2010-06-02

Similar Documents

Publication Publication Date Title
DE69930374D1 (de) Gfr-alpha3 und seine verwendungen
Gilchrist et al. Molecular basis of oocyte-paracrine signalling that promotes granulosa cell proliferation
Liu et al. INSL5 is a high affinity specific agonist for GPCR142 (GPR100)
Touhara et al. Functional identification and reconstitution of an odorant receptor in single olfactory neurons
Zhang et al. Organization of signaling complexes by PDZ-domain scaffold proteins
Wang et al. Cloning and expressional characterization of a novel galanin receptor: identification of different pharmacophores within galanin for the three galanin receptor subtypes
Eagle et al. ULBP6/RAET1L is an additional human NKG2D ligand
Chang et al. Proteolytic cleavage of the EMR2 receptor requires both the extracellular stalk and the GPS motif
CA2174529A1 (en) Dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) and uses thereof
DE69838334D1 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
ATE191503T1 (de) Somatostatinrezeptoren
Lu et al. Characterization of a regiospecific epivancosaminyl transferase GtfA and enzymatic reconstitution of the antibiotic chloroeremomycin
HUP0302339A2 (hu) Emlõs receptoralegység-fehérjék, megfelelõ reagensek és eljárások
CN100558899C (zh) 生长激素融合蛋白
WO2003020932A1 (en) Novel secretory proteins and dna thereof
Denkberg et al. Recombinant human single‐chain MHC‐peptide complexes made from E. coli by in vitro refolding: functional single‐chain MHC‐peptide complexes and tetramers with tumor associated antigens
JP6141205B2 (ja) 窒化ケイ素(Si3N4)親和性ペプチド、及びその利用
MX9709338A (es) Receptor de transmembrana-siete de tipo c5a.
WO2002102847A1 (fr) Nouveau ligand et son adn
Oleinikov et al. A single-headed dimer of Escherichia coli ribosomal protein L7/L12 supports protein synthesis
IL138585A0 (en) Vertebrate batched -2 protein
WO2001055103A3 (en) Chimeric neuropeptide y receptors
Leprince et al. c-ets-1 DNA binding to the PEA3 motif is differentially inhibited by all the mutations found in v-ets.
EP1693456A4 (en) FOR A G-PROTEIN-COUPLED RECEPTOR-CODING GENE AND ITS GENE-PRODUCT
Leprince et al. The chicken cellular progenitor of the v-ets oncogene, p68c-ets-1, is a nuclear DNA-binding protein not expressed in lymphoid cells of the spleen.